This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SAP And MolecularHealth Join Forces To Shape The Future Of Personalized Cancer Treatment

WALLDORF, Germany and NEW YORK, Nov. 12, 2012 /PRNewswire/ --   SAP AG (NYSE: SAP) and MolecularHealth, a leader in clinico-molecular informatics™, today announced that they have joined forces to improve oncologists' clinical decision-making and enhance the quality of care for cancer patients. A personalized cancer treatment services offering from MolecularHealth based on the SAP HANA® platform aims to translate terabytes of clinical, molecular and drug data into real-time and effective treatment choices for each individual patient. Benefitting from the unprecedented speed and performance of SAP HANA, the new offering is intended to successfully tackle the challenges of "big data," complex analytics, scalability and increasing healthcare industry costs. The solution is planned to be deployable in the cloud, on premise or in a hybrid model, as well as to be made available via mobile devices. The collaboration with MolecularHealth, recently formalized in an original equipment manufacturing (OEM) agreement, underlines SAP's commitment to supporting the paradigm-shifting information-driven revolution in personalized cancer treatment.

(Logo: http://photos.prnewswire.com/prnh/20110126/AQ34470LOGO)

Oncologists constantly face the challenge of identifying the correct treatment approach for an individual patient with cancer. This decision involves choosing the most effective medications with the least toxicity, or "personalizing" treatment for a specific patient based on the unique characteristics of their cancer.

"The growing numbers of available therapies and the rapidly expanding body of biomedical knowledge have led to great hope for treating patients, but at the same time there are increasing challenges due to the complexity in the clinical decision-making process. But today the practice of medicine is undergoing a technology-driven revolution to realize the goals of truly personalizing therapy and improving clinical efficiency," said Lloyd K. Everson, M.D., former vice-chairman and member of the Board of Directors of US Oncology and former member of the Board of Directors, president and chief operating officer of American Oncology Resources, Inc. "MolecularHealth has taken a unique approach to the integrated analysis of clinical and genetic data. The company is contextualizing these data with drug-related information for precise and safer treatment considerations by doctors. Powered by SAP HANA, MolecularHealth's personalized cancer therapy solutions aim to help oncologists achieve the potential of precision medicine."

There have been extensive advances in cancer treatment over the years, but many if not most cancers, especially in advanced stages, remain difficult to treat. Personalized cancer therapy seeks to dramatically improve these poor outcomes. Recent advances in technology -- particularly genome sequencing -- enable analyzing a patient's individual cancer and matching findings to existing drug choices. By conducting genomic sequencing on both a patient's normal cells and cancer cells, and then examining the differences that may have an impact on the disease, key clinical insights can be gleaned. Personalized medicine aims to achieve a higher effectiveness of drug selection and an improved understanding and subsequent avoidance of adverse side effects.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs